View Post

Radiation after surgery triples survival for a type of pediatric brain tumor

In Clinical Trials by Barbara Jacoby

By: St. Jude Children’s Research Hospital From: medicalxpress.com Radiation immediately following surgery in children with ependymoma, the third most common pediatric brain tumor, can nearly triple survival. The results are part of a Children’s Oncology Group (COG) clinical trial led by Thomas E. Merchant, D.O., Ph.D., of St. Jude Children’s Research Hospital. The findings appear as an advance online publication …

View Post

Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial

In Clinical Trials by Barbara Jacoby

From: mesothelioma.net An exciting new immunotherapy treatment is now being tested in a phase I clinical trial that is still recruiting for participants. This provides a unique opportunity for patients who qualify to get access to an innovative medicine with great promise. Known as CAR T-cell therapy, this new treatment uses gene therapy to modify a patient’s immune system cells. …

View Post

Digital Pills May Be on the Horizon in Cancer Care

In Clinical Trials by Barbara Jacoby

By: Andrew Smith From: onclive.com There have been many efforts in recent years to improve patient adherence to oncology medications. Sticking to a regime that causes adverse events is not easy, and sometimes simple forgetfulness is to blame, but intervention by providers has been shown to work.1 Now, oncologists may soon have 1 more tool in the form of digital …

View Post

Moving Away From IP Chemotherapy in Advanced Ovarian Cancer

In Clinical Trials by Barbara Jacoby

By: Bradley J. Monk, MD From: onclive.com The treatment of women with advanced-stage epithelial ovarian cancer (EOC) is aggressive surgical cytoreduction and platinum-based combination chemotherapy. The timing and the extent of surgery have direct implications on the selection of subsequent treatment of patients with EOC. Frontline chemotherapeutic regimens have evolved through a series of large multi-institutional randomized clinical trials that …

View Post

Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab

In Clinical Trials by Barbara Jacoby

At ASCO-SITC Clinical Immuno-Oncology Symposium From: digitaljournal.com – Preliminary data suggests the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior checkpoint inhibitor therapy – Median overall survival not yet reached with median follow up of 14.4 months in Cohort A – Improved survival observed in patients with low CD8+ “cold” tumor at baseline …

View Post

DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM

In Clinical Trials by Barbara Jacoby

From: financialbuzz.com DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that its Phase 2 study testing VAL-083 in patients with newly diagnosed glioblastoma multiforme (GBM) has achieved its halfway enrollment point. This trial, targeted to enroll up to thirty patients, is a single-arm, open-label study …

View Post

Immatics Announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers

In Clinical Trials by Barbara Jacoby

Source: Immatics From: pipelinereview.com Immatics today announced a collaboration with Roche to evaluate the safety and efficacy of IMA101, Immatics’ investigational autologous cell therapy, in combination with atezolizumab (TECENTRIQ®), in patients with solid cancers. IMA101 is a personalized, multi-targeted investigational immunotherapy for the treatment of multiple advanced / metastatic solid tumors. IMA101 is based on Immatics’ ACTolog® approach, which follows …

View Post

Patient-reported symptoms offer insight for clinical trials

In Clinical Trials by Barbara Jacoby

By: University of North Carolina at Chapel Hill School of Medicine From: medicalxpress.com University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators found that allowing patients to write, in their own words, about treatment-related symptoms they experienced while participating in clinical trials can provide valuable information. In a first-of-its-kind study published in the Journal of the American Medical …

View Post

Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

In Clinical Trials by Barbara Jacoby

Source: Cotinga Pharmaceuticals Inc. From: globenewswire.com Independent Dose Escalation Committee (DEC) recommends continuing the study at an increased dose Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has commenced dosing patients in the second cohort of its ongoing …

View Post

Pangea® Laboratory to License Bladder CARE™ Technology from Zymo Research

In Clinical Trials by Barbara Jacoby

Source: Pangea Laboratory From: prnewswire.com Non-invasive, epigenetic-based test for bladder cancer detection Pangea® Laboratory announced today the licensing of a new urine-based Laboratory Developed Test (LDT) for bladder cancer detection. Commercialized and sold under the name Bladder CARE™, the test is non-invasive, cost-effective and epigenetic-based. Urine samples for the Bladder CARE™ test can be collected comfortably at home or at …